Michael Nutter Completed Cases Celgene Corp. v. Natco Pharma Ltd., et al., Case No. 10-cv-5197 (SDW) (MCA) (D.N.J.) Patent infringement action regarding clients Natco Pharma’s and Watson Laboratories’ ANDA to make a generic version of the multiple myeloma drug Revlimid®, the active ingredient of which is lenalidomide. Case settled on terms favorable to Watson and Natco. Auxilium Pharmaceuticals, Inc., et al. v. Watson Laboratories, Inc., et al., Case No. 12-cv-3084 (JLL) (MAH) (D.N.J.) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the low-testosterone drug Testim® 1% Gel, the active ingredient of which is testosterone. Bench trial held before Judge Linares in September 2014. District court found all patents-in-suit invalid. No appeal was filed. Eli Lilly and Company, et al. v. Accord Healthcare, Inc., USA, et al., Case No. 14-cv-389-SEB-TAB (S.D.Ind.) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the oral antiplatelet drug Effient®, the active ingredient of which is prasugrel. Case settled on terms favorable to Watson. Acorda Therapeutics, Inc. v. Actavis Laboratories FL, Inc., Case No. 14-cv-882-LPS (D.Del.) Patent infringement action regarding client Actavis Laboratories’ ANDA to make a generic version of the drug Ampyra®, which is an extended-release tablet prescribed to improve walking in patients with multiple sclerosis. The active ingredient in Ampyra® is dalfampridine. Case settled on terms favorable to Actavis. Forest Laboratories, Inc., et al. v. Apotex Corp., et al., Case No. 14-cv-200-LPS (D.Del) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the Alzheimer’s drug Namenda XR®, the active ingredient of which is memantine hydrochloride. Case against Watson Laboratories voluntarily dismissed due to parent company Actavis’ acquisition of Plaintiff Forest Laboratories. In re Armodafinil Patent Litigation, MDL No. 10-cv-2200-GMS (D.Del.) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the sleep apnea medication Nuvigil®, the active ingredient of which is armodafinil. Bench trial held July 17-20, 2012. District court found the polymorph patent-in-suit valid and infringed. Appellate argument held March 6, 2014. Case subsequently settled on terms favorable to Watson. Astrazeneca LP, et al. v. Andrx Pharmaceuticals, Ltd., Case No. 99-cv-9887 (BSJ) (S.D.N.Y.) Represented client Andrx in damages portion of patent infringement litigation regarding Andrx’s ANDA to make a generic version of the heartburn medication Prilosec®, the active ingredient of which is omeprazole. Astrazeneca agreed to a consent judgment of ZERO damages after pretrial conference. Astra chose not to appeal. Endo Pharmaceuticals, Inc., et al. v. Watson Laboratories, Inc., Case No. 10-cv-138-GMS (D.Del.) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the lidocaine transdermal patch Lidoderm®. Trial held February 2012. Case settled on terms favorable to Watson.
Attorney advertising materials - © 2016 Winston & Strawn LLP
1
Endo Pharmaceuticals, Inc. v. Watson Laboratories, Inc., et al., Case No. 11-cv-575-GMS (D.Del.) Second patent infringement action regarding client Watson Laboratories ANDA to make a generic version of the post-herpetic neuralgia transdermal patch Lidoderm®, the active ingredient which is lidocaine. Case settled on terms favorable to Watson. Mallinckrodt, Inc. v. Watson Laboratories, Inc. - Florida, Case No. 10-cv-6424 (FSH)(PS) (D.N.J.) Patent infringement action regarding client Watson Laboratories’ ANDA to make a generic version of the pain reliever Exalgo®, the active ingredient of which is hydromorphone hydrochloride. Case settled on terms favorable to Watson. Bayer Schering Pharma AG, et al. v. Barr Laboratories, Inc., et al., Case No. 10-cv-00872-HDM-RJJ (D.Nev.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the oral contraceptive Yaz®, the active ingredient of which is a combination of drospirenone and ethinyl estradiol. Case settled on terms favorable to Barr. In re Desloratadine Patent Litigation, MDL No. 1851 (D.N.J.) Patent infringement action regarding client Sun Pharmaceutical’s ANDA to make a generic version of the allergy medication Clarinex®, the active ingredient of which is desloratadine. Case settled on terms favorable to Sun. Teva Pharmaceuticals USA, Inc., et al. v. Bayer Schering Pharma AG, et al., Case No. 10-cv-04340 (S.D.N.Y.) Declaratory judgment action regarding client Barr Laboratories’ ANDA to make a generic version of the oral contraceptive Yaz®, the active ingredient of which is a combination of drospirenone and ethinyl estradiol. Case settled on terms favorable to Barr. Astrazeneca LP, et al. v. Barr Laboratories, Inc., Case No. 08-305-JJF (D.Del) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of Entocort® EC, a capsule used to treat mild to moderate Crohn’s disease affecting the ileum and/or ascending colon, the active ingredient of which is budesonide. Case settled on terms favorable to Barr. Cephalon, Inc., et al. v. Barr Laboratories, Inc., et al., Case No. 08-455 (D.Del) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the pain reliever Fentora®, the active ingredient of which is fentanyl. Case settled on terms favorable to Barr. Watson Laboratories, Inc. v. Barr Laboratories, Inc., et al., Case No. 08-793-GMS (D.Del.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of Oxytrol®, a transdermal system used to treat overactive bladders, the active ingredient of which is oxybutynin. Case settled on terms favorable to Barr. PDL BioPharma, Inc. v. Sun Pharmaceutical Industries Ltd., Case No. 07-1788 (KSH) (PJS) (D.N.J.) Patent infringement action regarding client Sun Pharmaceutical’s ANDA to make a generic version of the acute hypertension drug Cardene® I.V., the active ingredient of which is nicardipine hydrochloride. Case voluntarily dismissed.
© 2016 Winston & Strawn LLP
2
Ortho-McNeil Pharmaceutical, Inc. v. Caraco Pharmaceutical Laboratories Ltd., et al., Case No. 06-3533 (DMC) (MF) (D.N.J.) Patent infringement action regarding client Caraco Pharmaceutical’s ANDA to make a generic version of the pain reliever Ultracet®, the active ingredient of which is a combination of tramadol and acetaminophen. Obtained favorable summary judgment ruling of patent invalidity. Case settled on terms favorable to Caraco. Bayer Schering AG, et al. v. Barr Laboratories, Inc., Case No. 05-2308 (JPS)(ES) (D.N.J.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the oral contraceptive Yasmin®, the active ingredient of which is a combination of drospirenone and ethinyl estradiol. Obtained favorable district court decision of patent invalidity after multi-week trial. Confirmed on appeal. Cephalon, Inc., et al. v. Barr Laboratories, Inc., Case No. 05-29-JJF (D.Del.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the pain reliever Actiq®, the active ingredient of which is fentanyl. Case settled on terms favorable to Barr. Eli Lilly & Co. v. Barr Laboratories, Inc., Case No. 04-1957-RLY-JMS (S.D.Ind.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the bipolar disorder drug Zyprexa®, the active ingredient of which is olanzapine. Case voluntarily dismissed. Eli Lilly & Co. v. Barr Laboratories, Inc., Case No. 02-1844-SEB-VSS (S.D.Ind.) Patent infringement action regarding client Barr Laboratories’ ANDA to make a generic version of the osteoporosis drug Evista®, the active ingredient of which is raloxifene. Case administratively closed. Savient Pharmaceuticals, Inc., et al. v. Duramed Pharmaceuticals, Inc. and Barr Laboratories, Inc., Case No. 00-4509 (DMC) (D.N.J.) Patent infringement action regarding client Duramed Pharmaceutical’s ANDA to make a generic version of the oral contraceptive Mircette®, the active ingredient of which is a combination of desogestrel and ethinyl estradiol. Case settled on terms favorable to Duramed and Barr.
© 2016 Winston & Strawn LLP
3
